Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Doctors say changes to US vaccine recommendations are confusing parents and could harm kids - 2Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- 3Share your pick for the riding area that characterizes your surf undertakings!
- 4Venezuelans in Madrid celebrate Maduro's capture
- 5Banks for High Fixed Store Rates: Amplify Your Reserve funds
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- Illegal entries into Germany halve over two years, border police say
- Most loved Public Dish: Which One Addresses Its Nation Best?
- German police 'cleared path for fascists with batons,' protesters say
- 37 Things Just Individuals Experiencing childhood during the 80s Will Comprehend
- Soldiers seize power in Guinea-Bissau and detain the president
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
- 6 Famous Urban communities for Shopping on the planet
